Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c; Offers FY22 Revenue Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $35.96 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2022 revenue of $155-165 million, versus the consensus of $160 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Stifel Canada Starts BlackBerry (BB) at Buy
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance